JP2025020148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2025020148A5 JP2025020148A5 JP2024179270A JP2024179270A JP2025020148A5 JP 2025020148 A5 JP2025020148 A5 JP 2025020148A5 JP 2024179270 A JP2024179270 A JP 2024179270A JP 2024179270 A JP2024179270 A JP 2024179270A JP 2025020148 A5 JP2025020148 A5 JP 2025020148A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor antagonist
- crf
- molecular weight
- use according
- low molecular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545406P | 2017-08-14 | 2017-08-14 | |
| US62/545,406 | 2017-08-14 | ||
| JP2019572817A JP7398963B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| PCT/US2018/046760 WO2019036503A1 (en) | 2017-08-14 | 2018-08-14 | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS |
| JP2023146415A JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146415A Division JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025020148A JP2025020148A (ja) | 2025-02-12 |
| JP2025020148A5 true JP2025020148A5 (https=) | 2025-03-05 |
Family
ID=65362494
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572817A Active JP7398963B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2023146415A Active JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2024179270A Pending JP2025020148A (ja) | 2017-08-14 | 2024-10-11 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572817A Active JP7398963B2 (ja) | 2017-08-14 | 2018-08-14 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
| JP2023146415A Active JP7573080B2 (ja) | 2017-08-14 | 2023-09-08 | 副腎皮質刺激ホルモン放出因子受容体拮抗薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (9) | US20210361664A1 (https=) |
| EP (1) | EP3628005A4 (https=) |
| JP (3) | JP7398963B2 (https=) |
| KR (2) | KR20250022913A (https=) |
| CN (2) | CN118845788A (https=) |
| AU (2) | AU2018317398A1 (https=) |
| BR (1) | BR112020002967A2 (https=) |
| CA (1) | CA3064464A1 (https=) |
| EA (1) | EA202090450A1 (https=) |
| MX (2) | MX2019015320A (https=) |
| WO (1) | WO2019036503A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015112642A1 (en) | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| CN118845788A (zh) | 2017-08-14 | 2024-10-29 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
| EP4438124A3 (en) | 2018-04-27 | 2024-12-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| TW202116324A (zh) * | 2019-07-19 | 2021-05-01 | 美商雲杉生物科技股份有限公司 | 治療先天性腎上腺增生之方法 |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| BR112023002497A2 (pt) * | 2020-08-12 | 2023-05-02 | Spruce Biosciences Inc | Métodos e composições para tratamento da síndrome dos ovários policísticos |
| JP2023540223A (ja) * | 2020-08-26 | 2023-09-22 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| WO2025188842A1 (en) * | 2024-03-08 | 2025-09-12 | Spruce Biosciences, Inc. | Amorphous solid dispersion of tildacerfont formulations |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE177101T1 (de) | 1992-12-17 | 1999-03-15 | Pfizer | Pyrrolopyrimidine als crf antagonisten |
| JP3356291B2 (ja) | 1996-02-07 | 2002-12-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｃｒｆレセプター拮抗薬としてのピラゾロピリミジン類 |
| IL127871A0 (en) | 1996-07-24 | 1999-10-28 | Du Pont Pharm Co | Azolo triazines and pyrimidines |
| HU228962B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo triazines, pharmaceutical compositions containing them and use of the compounds |
| IL127566A0 (en) | 1996-08-28 | 1999-10-28 | Pfizer | Substituted 6,5-hetero- bicyclic derivatives |
| EP1049699B1 (en) | 1998-01-28 | 2004-04-21 | Bristol-Myers Squibb Pharma Company | Pyrazolotriazines as crf antagonists |
| IL137019A (en) | 1998-01-28 | 2010-11-30 | Du Pont Pharm Co | 2,7 - dimethyl - 4 - (substituted amino) - 8 - arylpyrazolo [1,5-a] triazine derivatives and pharmaceutical compositions containing them |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| WO2000059908A2 (en) | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| EP1218381B1 (en) | 1999-09-30 | 2006-12-06 | Neurogen Corporation | AMINO SUBSTITUTED PYRAZOLO¬1,5-a|-1,5-PYRIMIDINES AND PYRAZOLO¬1,5-a|-1,3,5-TRIAZINES |
| JP2003516353A (ja) | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
| BR0208357A (pt) | 2001-03-13 | 2004-06-29 | Bristol Myers Squibb Pharma Co | Composto, composição farmacêutica, método de antagonização de um receptor de fator de liberação de corticotropina (crf), método de tratamento de disfunção, método de triagem de ligantes, método de detecção de receptores de crf, método de inibição da ligação de crf, artigo industrializado e usos do composto |
| US20050085479A1 (en) | 2003-08-27 | 2005-04-21 | Pharmacia Corporation | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury |
| CA2547639A1 (en) | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| CA2550948A1 (en) | 2003-12-22 | 2005-07-14 | Sb Pharmco Puerto Rico Inc. | Crf receptor antagonists and methods relating thereto |
| WO2005079868A2 (en) | 2004-02-13 | 2005-09-01 | Sb Pharmco Puerto Rico Inc | Crf receptor antagonists, their preparations, their pharmaceutical composition and their uses |
| WO2005079807A1 (en) | 2004-02-13 | 2005-09-01 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists |
| WO2006124047A2 (en) * | 2004-08-13 | 2006-11-23 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| AU2006227300B2 (en) | 2005-03-21 | 2012-02-02 | Eli Lilly And Company | Imidazopyridazine compounds |
| CN101516835A (zh) | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| EP2094709B1 (en) * | 2006-09-20 | 2010-09-15 | Eli Lilly And Company | Thiazole pyrazolopyrimidines as crf1 receptor antagonists |
| AU2007297481B2 (en) | 2006-09-20 | 2012-03-08 | Eli Lilly And Company | Thiophene pyrazolopyrimidine compounds |
| US8952207B2 (en) | 2007-09-11 | 2015-02-10 | The University Of Houston System | Copper-catalyzed C—H bond arylation |
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| WO2010039678A1 (en) | 2008-10-02 | 2010-04-08 | Eli Lilly And Company | Thiazolyl-pyrazolopyrimidine compounds as synthetic intermediates and related synthetic processes |
| EP4718073A2 (en) * | 2008-12-24 | 2026-04-01 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for congenital adrenal hyperplasia |
| PL2519230T3 (pl) * | 2009-12-31 | 2019-05-31 | Marius Pharmaceuticals Llc | Modulacja rozpuszczalności, stabilności, absorpcji, metabolizmu i profilu farmakokinetycznego leków lipofilowych przez sterole |
| US9750568B2 (en) | 2012-03-08 | 2017-09-05 | Medtronic Ardian Luxembourg S.A.R.L. | Ovarian neuromodulation and associated systems and methods |
| HK1207304A1 (en) | 2012-04-23 | 2016-01-29 | Hmnc Value Gmbh | Crhr1 antagonists for use in the treatment of patients having crh overactivity |
| WO2015112642A1 (en) * | 2014-01-21 | 2015-07-30 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia |
| AU2016242867B2 (en) | 2015-03-31 | 2020-11-05 | May Health Us Inc. | Methods and systems for the manipulation of ovarian tissues |
| CN118845788A (zh) | 2017-08-14 | 2024-10-29 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
| EA202090321A1 (ru) | 2017-08-14 | 2020-09-24 | Спрюс Биосайнсес, Инк. | Антагонисты рецептора кортикотропин-рилизинг фактора |
| EP4438124A3 (en) | 2018-04-27 | 2024-12-18 | Spruce Biosciences, Inc. | Methods for treating testicular and ovarian adrenal rest tumors |
| CA3121920A1 (en) | 2018-12-07 | 2020-06-11 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| US20200255436A1 (en) | 2019-02-12 | 2020-08-13 | Spruce Biosciences, Inc. | Corticotropin releasing factor receptor antagonists |
| TW202116324A (zh) | 2019-07-19 | 2021-05-01 | 美商雲杉生物科技股份有限公司 | 治療先天性腎上腺增生之方法 |
| BR112023002497A2 (pt) | 2020-08-12 | 2023-05-02 | Spruce Biosciences Inc | Métodos e composições para tratamento da síndrome dos ovários policísticos |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
| MX2024006064A (es) | 2021-11-19 | 2024-05-30 | Spruce Biosciences Inc | Composicion cristalina de tildacerfont y metodos de uso y preparacion de la misma. |
-
2018
- 2018-08-14 CN CN202410709847.0A patent/CN118845788A/zh active Pending
- 2018-08-14 JP JP2019572817A patent/JP7398963B2/ja active Active
- 2018-08-14 MX MX2019015320A patent/MX2019015320A/es unknown
- 2018-08-14 EP EP18846689.0A patent/EP3628005A4/en active Pending
- 2018-08-14 CN CN201880038569.3A patent/CN110996943A/zh active Pending
- 2018-08-14 KR KR1020257004457A patent/KR20250022913A/ko active Pending
- 2018-08-14 WO PCT/US2018/046760 patent/WO2019036503A1/en not_active Ceased
- 2018-08-14 BR BR112020002967-0A patent/BR112020002967A2/pt not_active Application Discontinuation
- 2018-08-14 CA CA3064464A patent/CA3064464A1/en active Pending
- 2018-08-14 KR KR1020207004095A patent/KR20200040761A/ko not_active Ceased
- 2018-08-14 AU AU2018317398A patent/AU2018317398A1/en not_active Abandoned
- 2018-08-14 US US16/639,541 patent/US20210361664A1/en not_active Abandoned
- 2018-08-14 EA EA202090450A patent/EA202090450A1/ru unknown
-
2019
- 2019-04-18 US US16/388,620 patent/US10849908B2/en active Active
- 2019-12-16 MX MX2023000501A patent/MX2023000501A/es unknown
-
2020
- 2020-10-05 US US17/063,592 patent/US11344557B2/en active Active
- 2020-10-22 US US17/078,054 patent/US11007201B2/en active Active
-
2021
- 2021-06-25 US US17/359,411 patent/US11351177B2/en active Active
- 2021-06-25 US US17/359,414 patent/US11311549B2/en active Active
-
2022
- 2022-01-27 US US17/586,228 patent/US20220143037A1/en not_active Abandoned
- 2022-12-09 US US18/078,649 patent/US20230321112A1/en active Pending
-
2023
- 2023-01-13 AU AU2023200189A patent/AU2023200189B2/en active Active
- 2023-04-26 US US18/307,718 patent/US12115166B2/en active Active
- 2023-09-08 JP JP2023146415A patent/JP7573080B2/ja active Active
-
2024
- 2024-10-11 JP JP2024179270A patent/JP2025020148A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025020148A5 (https=) | ||
| Sitruk-Ware et al. | Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills | |
| JP2656958B2 (ja) | ホルモン依存性腫瘍治療剤 | |
| Sitruk-Ware | New progestagens for contraceptive use | |
| Genazzani et al. | Long-term low-dose dehydroepiandrosterone oral supplementation in early and late postmenopausal women modulates endocrine parameters and synthesis of neuroactive steroids | |
| CN102811730B (zh) | 孕激素作为糖皮质激素增敏剂的使用 | |
| Sitruk-Ware et al. | The use of newer progestins for contraception | |
| Africander et al. | Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception | |
| Schindler et al. | Reprint of classification and pharmacology of progestins | |
| Krattenmacher | Drospirenone: pharmacology and pharmacokinetics of a unique progestogen | |
| Sitruk-Ware | Pharmacology of different progestogens: the special case of drospirenone | |
| Fruzzetti et al. | Review of clinical experience with estradiol in combined oral contraceptives | |
| Schindler | The “newer” progestogens and postmenopausal hormone therapy (HRT) | |
| Kaore et al. | Novel actions of progesterone: what we know today and what will be the scenario in the future? | |
| IL286048B2 (en) | Abiraterone decanoate and its pharmaceutical salts, pharmaceutical preparations containing them, their uses and preparation | |
| CA2326654A1 (en) | Use of steroidal alkaloid derivatives as inhibitors of hedgehog signaling pathways | |
| Requena et al. | Oral contraceptives in dermatology | |
| Voutsadaki et al. | Hypogonadism in adolescent girls: treatment and long-term effects | |
| JPWO2021016208A5 (https=) | ||
| Tatsumi et al. | Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins | |
| JP2008534533A5 (https=) | ||
| CN106232107A (zh) | 用于抗孕激素的阴道递送的制剂和方法 | |
| JP6343619B2 (ja) | プロゲステロン依存性病態を処置する方法およびその組成物 | |
| Noori et al. | Effects of estrogen and progesterone used in oral contraceptive pills: A review | |
| EP2026818B1 (en) | Combination of steroids having transporter-enhanced corticosteroid activity |